Literature DB >> 9527799

Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

R Wise1, S Jones, I Das, J M Andrews.   

Abstract

A single 200-mg dose of clinafloxacin was given orally to each of nine healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharidin-induced inflammatory fluid, and urine over the following 24 h (48 h in the case of urine). The mean maximum concentration in plasma was 1.34 microg/ml at a mean time of 1.8 h postdose. The mean maximum concentration in the inflammatory fluid was 1.3 microg/ml at 3.8 h postdose. The mean elimination half-life of clinafloxacin in plasma was 5.65 h. The overall penetration into the inflammatory fluid was 93.1%, as assessed by determining the ratio of area under the concentration-time curves. Recovery of clinafloxacin in urine was 58.8% by 24 h and 71.8% by 48 h postdose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527799      PMCID: PMC105427          DOI: 10.1128/AAC.42.2.428

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.

Authors:  J H Johnson; M A Cooper; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors:  R Wise; D Mortiboy; J Child; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

6.  The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.

Authors:  N J Bron; M B Dorr; T G Mant; C L Webb; A B Vassos
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

7.  The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.

Authors:  J Child; J Andrews; F Boswell; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

8.  In vitro activity of PD 127,391, an enhanced-spectrum quinolone.

Authors:  R Wise; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

9.  Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

  9 in total
  8 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Pharmacokinetics of clinafloxacin after single and multiple doses.

Authors:  E J Randinitis; J I Brodfuehrer; I Eiseman; A B Vassos
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.